Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer

Clinical Cancer Research

Volumn 17, Issue 18, 2011, Pages 6052-6060

  Naing, Aung ^a   Kurzrock, Razelle ^a   Burger, Angelika ^c   Gupta, Sachin ^c   Lei, Xiudong ^a   Busaidy, Naifa ^a   Hong, David ^a   Chen, Helen X ^b   Doyle, Lawrence A ^b   Heilbrun, Lance K ^c   Rohren, Eric ^a   Ng, Chaan ^a   Chandhasin, Chandtip ^a   LoRusso, Patricia ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALUMINUM MAGNESIUM HYDROXIDE; ASPARTATE AMINOTRANSFERASE; BIOTENE; CAPHASOL; CIXUTUMUMAB; CREATININE; DIPHENHYDRAMINE; FLUORODEOXYGLUCOSE F 18; INSULIN; LIDOCAINE; MOUTHWASH; ORAL ANTIDIABETIC AGENT; SODIUM DIHYDROGEN PHOSPHATE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SUCRALFATE; TEMSIROLIMUS; UNCLASSIFIED DRUG; VALACICLOVIR;

ACUTE KIDNEY FAILURE; ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD SAMPLING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EWING SARCOMA; EYE TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROTEIN KINASE INHIBITORS; SIROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052831572     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2979     Document Type: Conference Paper

References (15)

1. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
2. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005;4:1533-40. (Pubitemid 41556435)
3. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932-40. (Pubitemid 46474636)
4. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8. (Pubitemid 43259931)
5. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ. The insulin-like growth factor-1 targeting antibody, CP-751871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-71.
6. Denlinger CS, Blanchard R, Xu L, Bernaards C, Litwin S, Spittle C, et al. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009;65:97-105.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders JN, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
8. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjhamin R, et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 2010;16:2458-65.
9. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini P-L, Astolfi A, et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 2011;30:2730-40.
10. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2009;11:129-35.
11. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-7.
12. Brepoels L, Stroobants S, Verhoef G, De Groot T, Mortelmans L, De Wolf-Peeters C et. al. (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. J Nucl Med 2009;50:1102-9.
13. Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA. Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res 2008;14:3416-26.
14. Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, et. al. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 2009;27:2697-704.
15. De Giorgi U, Amadori D. [18F]Fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy. J Clin Oncol 2010;28:e236-7.